Literature DB >> 7797914

Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization.

B Watson1, E Rothstein, H Bernstein, A Arbeter, A Arvin, S Chartrand, D Clements, M L Kumar, K Reisinger, M Blatter.   

Abstract

Four hundred nineteen children and adolescents immunized with live varicella vaccine 4-6 years earlier were enrolled in a study to evaluate the safety and immune response to a booster dose containing approximately 3300 pfu of virus. Of the subjects, 99% (414/419) maintained antibody to varicella zoster virus (VZV) with a geometric mean titer of 25.7 and mean stimulation index (SI) for VZV-specific lymphoproliferation response of 40.3 +/- 5.3 (SE). Some 7-10 days after the booster immunization, seropositivity rates increased to 100% (302/302), and GMT was 143.6 (anamnestic response). At 6 weeks after the booster inoculation, a subset of subjects had 100% seropositivity (74/74) with a GMT of 218.8 and an SI of 58.6. After 3 months, seropositivity was 100% (358/358), GMT was 119.0, and SI was 61.4.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7797914     DOI: 10.1093/infdis/172.1.217

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients.

Authors:  Martina Prelog; Jörn Schönlaub; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-11-15       Impact factor: 3.714

Review 2.  Successes and challenges in varicella vaccine.

Authors:  Orestis Papaloukas; Georgia Giannouli; Vassiliki Papaevangelou
Journal:  Ther Adv Vaccines       Date:  2014-03

Review 3.  Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses.

Authors:  Paolo Bonanni; Anne Gershon; Michael Gershon; Andrea Kulcsár; Vassiliki Papaevangelou; Bernard Rentier; Catherine Sadzot-Delvaux; Vytautas Usonis; Timo Vesikari; Catherine Weil-Olivier; Peter de Winter; Peter Wutzler
Journal:  Pediatr Infect Dis J       Date:  2013-07       Impact factor: 2.129

4.  Vaccination to prevent varicella and shingles.

Authors:  J Breuer
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

5.  Effectiveness of varicella vaccine as post-exposure prophylaxis: a meta-analysis.

Authors:  Daoyong Chen; Yue Li; Qiangsong Wu
Journal:  Hum Vaccin Immunother       Date:  2021-12-10       Impact factor: 3.452

Review 6.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

7.  Immunogenicity and safety of different schedules of 2-dose varicella vaccination in China.

Authors:  Xuan Deng; Wenqing Xu; Rui Yan; Haiping Chen; Wei Shen; Min Zhang; Tengjie Wu; Bin Xu; Hanqing He; Yanli Ma
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

8.  Varicella: efficacy of two-dose vaccination in childhood.

Authors:  Peter Wutzler; Markus Knuf; Johannes Liese
Journal:  Dtsch Arztebl Int       Date:  2008-08-15       Impact factor: 5.594

Review 9.  Impact of varicella vaccine on varicella-zoster virus dynamics.

Authors:  D Scott Schmid; Aisha O Jumaan
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 10.  Alphaherpesvirus Vaccines.

Authors:  Clare Burn Aschner; Betsy C Herold
Journal:  Curr Issues Mol Biol       Date:  2020-09-23       Impact factor: 2.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.